Oncodesign Precision Medicine S.A. ((FR:ALOPM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncodesign Precision Medicine S.A. has launched the REVERT Study, officially titled ‘A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1.’ This study aims to evaluate the safety and effectiveness of OPM-101 in combination with pembrolizumab, an anti-PD-1 therapy, in patients with advanced melanoma who have developed resistance to anti-PD-1 treatments. The significance of this study lies in its potential to resensitize tumors to anti-PD-1 therapies, offering new hope for patients with limited treatment options.
The intervention being tested is OPM-101, a drug administered in combination with pembrolizumab. OPM-101 is given as hard gelatin capsules twice daily, with the goal of enhancing the effectiveness of pembrolizumab in treating resistant melanoma.
The study design is interventional, with a single-group model and an open-label format. It consists of two phases: Phase 1b involves dose escalation to determine the safest and most effective dose of OPM-101, while Phase 2a focuses on evaluating the treatment’s efficacy. The primary purpose of the study is treatment, with no masking involved.
The study is set to begin on June 13, 2025, with the primary completion date yet to be determined. The last update was submitted on June 24, 2025. These dates are crucial as they mark the progression and current status of the study.
The market implications of this study update could be significant for Oncodesign Precision Medicine, potentially boosting investor confidence and stock performance if the results show promise. In the competitive landscape of melanoma treatment, successful outcomes could position the company favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.